Methods
=======

The *in vitro* ability of G-CSF to improve neutrophil superoxide production has been previously demonstrated in ALF patients \[[@B1]\]. However, the *in vivo* effect on neutrophil function is unknown. Therefore G-CSF was given to three groups of ALF patients (*n* = 6) as a daily infusion at four different dosages (25, 50, 100 and 150 µg/m^2^). Superoxide production was measured after fMLP stimulation, before and at 24 and 96 h.

Results
=======

See table

G-CSF significantly enhanced superoxide production at 96 h (*P* \< 0.05). Furthermore, this effect was observed at doses below the standard therapeutic dose of 150 µg/m^2^. Further studies are needed to determine the therapeutic value of G-CSF in the prevention and treatment of infection in ALF patients.

  G-CSF                  Hours after G-CSF infusion   
  ------- -------------- ---------------------------- --------------
  25      221.4 (58.1)   267.9(62.7)                  382.7 (40.6)
  50      308.1 (17.2)   339.3 (56.3)                 592.0 (98.7)
  100     231.5 (65.2)   225.9 (52.6)                 317.5(82.2)
  150     217.4 (30.7)   357.0 (62.2)                 358.4 (45.4)
